{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-030408","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2026-06-29T11:05:56+00:00","discovered_at":"2026-06-29T11:10:00.267568+00:00","generated_at":"2026-06-29T11:10:31.860070+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tonix enrolls first patient in Phase 2 MDD study of TNX-102 SL (TONMYA)","bullets":["First patient enrolled in HORIZON, a potentially pivotal Phase 2 study of TNX-102 SL 5.6 mg as first-line monotherapy for major depressive disorder.","Primary endpoint: change from baseline in MADRS total score at Week 6; about 360 patients at ~30 US sites.","TNX-102 SL (TONMYA) was FDA approved for fibromyalgia in August 2025; MDD indication is investigational.","CEO notes TNX-102 SL targets poor sleep quality; prior signals in PTSD and fibromyalgia studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-030408","json":"https://secwatch.observer/filing/0001493152-26-030408.json","markdown":"https://secwatch.observer/filing/0001493152-26-030408.md","text":"https://secwatch.observer/filing/0001493152-26-030408.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000149315226030408/0001493152-26-030408-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000149315226030408/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T11:10:31.860070+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}